| | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis . . . |
Terminated |
12 Aug 2021 |
| | A 24-week multi-center, double-blind, placebo controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS) . . . |
Ongoing |
04 Jun 2020 |
| | A 24-week Treatment, Randomised, Parallel-group, Double blinded, Double- Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium bromide/Formoterol fumarate compared with Individual C . . . |
Completed |
11 Mar 2020 |
| | A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients ≠. . . |
Pending |
30 Nov -0001 |
| | A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis . . . |
Terminated |
12 Aug 2021 |
| | A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130 . . . |
Pending |
29 Dec 2021 |
| | A 52-week, multicenter, randomized, double-blind, double dummy, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for reduction of systemic corticostero . . . |
Terminated |
30 Mar 2021 |
| | A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma . . . |
Completed |
30 Mar 2021 |
| | A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis . . . |
Terminated |
05 Aug 2021 |
| | A 6-Month Safety, Efficacy, and Pharmacokinetic Trial of Delamanid in Pediatric Patients with Multi-Drug Resistant Tuberculosis . . . |
Completed |
09 Oct 2020 |
| | A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proli . . . |
Pending |
05 Oct 2021 |
| | A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension . . . |
Ongoing |
30 Dec 2020 |
| | A Double blind, Randomized, Placebo controlled, Single dose, Dose ascending Phase I Study to Evaluate the Safety, Tolerability and Pharmacodynamics (PD) of Niclosamide injectable (DWRX2003) following . . . |
Terminated |
16 Sep 2021 |
| | A double-blind randomized controlled trial on the efficacy and safety of metformin as an adjunct to lymecycline and topical adapalene plus benzoyl peroxide gel in the treatment of moderate to severe a . . . |
Completed |
30 Nov -0001 |
| | A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin As Adjunctive Therapy In Children 1 month through < 4 Years of Age with Partial Onset . . . |
Completed |
17 Jul 2019 |
| | A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the p . . . |
Ongoing |
30 Nov -0001 |
| | A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urtica . . . |
Ongoing |
23 Aug 2021 |
| | A multi-center, randomized, double-blind, active and placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic spontaneous Urticaria (CSU) in . . . |
Ongoing |
30 Mar 2021 |
| | A multi-center, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial to evaluate the safety and efficacy of pyronaridine-artesunate (Artecom®) in COVID-19 patients . . . |
Ongoing |
24 Sep 2021 |
| | A Multi-national, Multi-center, Randomized, Double-Blind, Active-Controlled, Phase III Study to Investigate the Efficacy and Safety of 'GC3107 (BCG Vaccine)' after Intradermal Administration in Health . . . |
Ongoing |
24 Jun 2021 |
| | A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenit . . . |
Ongoing |
21 May 2021 |
| | A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab T . . . |
Ongoing |
18 Jun 2021 |
| | A multicenter, openlabel, follow-up study to assess the longterm use of Lacosamide (flexible dose from 200 to 600 mg/day) used as monotherapy in subjects who completed SP0994 and received Lacosamide m . . . |
Completed |
23 Sep 2020 |
| | A multicenter, randomized, 52-week, double-blind, parallel group, active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma . . . |
Completed |
23 Apr 2020 |
| | A multicenter, randomized, double-blind, active-controlled, 2 week treatment, parallel-group study to assess the efficacy and safety of indacaterol acetate delivered via the Concept1 inhalation device . . . |
Completed |
30 Mar 2021 |